The Impact of Outpatient versus Inpatient Administration of CAR-T Therapies on Clinical, Economic, and Humanistic Outcomes in Patients with Hematological Cancer: A Systematic Literature Review
Open Access
Abstract
Although chimeric antigen receptor (CAR)-T cell therapies are typically administered in the inpatient setting, outpatient administration is rapidly expanding. However, there is limited summarized evidence comparing outcomes between outpatient and inpatient administration. This systematic literature review aims to compare the safety, efficacy, quality of life (QoL), costs, and healthcare resource utilization (HCRU) outcomes in patients with hematological cancer who are administered CAR-T therapy in an outpatient versus an inpatient setting. Publications (2016 or later) that reported the outcomes of interest in patients treated with a CAR-T therapy in both outpatient and inpatient settings, or only the outpatient setting, were reviewed. In total, 38 publications based on 21 studies were included. Safety findings suggested the comparable frequency of adverse events in the two settings. Eleven studies that reported data in both settings showed comparable response rates (80–82% in outpatient and 72–80% in inpatient). Improvements in the QoL were observed in both settings while costs associated with CAR-T therapy were lower in the outpatient setting. Although unplanned hospitalizations were higher in the outpatient cohort, overall HCRU was lower. Outpatient administration of CAR-T therapy appears to have comparable outcomes in safety, efficacy, and QoL to inpatient administration while reducing the economic burden.Keywords
Funding Information
- Janssen Scientific Affairs, LLC
- Legend Biotech USA, Inc.
This publication has 64 references indexed in Scilit:
- CD19 directed CAR T cell therapy in diffuse large B-cell lymphomaOncotarget, 2018
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic LeukemiaNew England Journal of Medicine, 2018
- Cytokine release syndrome (CRS) and neurotoxicity (NT) after CD19-specific chimeric antigen receptor- (CAR-) modified T cells.Journal of Clinical Oncology, 2017
- Economic burden of malignant blood disorders across Europe: a population-based cost analysisThe Lancet Haematology, 2016
- Current status of chimeric antigen receptor therapy for haematological malignanciesBritish Journal of Haematology, 2015
- Haematological cancer and quality of life: a systematic literature reviewBlood Cancer Journal, 2015
- T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trialThe Lancet, 2015
- Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic LeukemiaScience Translational Medicine, 2014
- Preferences for involvement in treatment decision making of patients with cancer: A review of the literatureEuropean Journal of Oncology Nursing, 2008
- The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions.Journal of Epidemiology and Community Health, 1998